135 related articles for article (PubMed ID: 23467445)
1. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin.
Nagata M; Kimura T; Suzumura T; Kira Y; Nakai T; Umekawa K; Tanaka H; Matsuura K; Mitsuoka S; Yoshimura N; Oka T; Kudoh S; Hirata K
Clin Med Insights Oncol; 2013; 7():31-9. PubMed ID: 23467445
[TBL] [Abstract][Full Text] [Related]
2. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 polymorphism as a predictive biomarker for amrubicin-induced neutropenia.
Takakuwa O; Oguri T; Uemura T; Kunii E; Nakao M; Hijikata H; Kawaguchi Y; Ohkubo H; Takemura M; Maeno K; Niimi A
Anticancer Res; 2014 Jul; 34(7):3517-22. PubMed ID: 24982363
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the risk of lung cancer associated with NAD(P)H: quinone oxidoreductase 1 (
Banerjee S
Mol Biol Res Commun; 2020 Sep; 9(3):111-115. PubMed ID: 33313330
[TBL] [Abstract][Full Text] [Related]
6. No association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and risk of hepatocellular carcinoma development in Turkish subjects.
Akkiz H; Bayram S; Bekar A; Akgöllü E; Ülger Y; Kaya BY; Sandikçi M; Özdil B
Asian Pac J Cancer Prev; 2010; 11(4):1051-8. PubMed ID: 21133623
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
Makino Y; Watanabe M; Makihara RA; Nokihara H; Yamamoto N; Ohe Y; Sugiyama E; Sato H; Hayashi Y
Asia Pac J Clin Oncol; 2016 Sep; 12(3):259-64. PubMed ID: 26948073
[TBL] [Abstract][Full Text] [Related]
8. NQO1 C609T polymorphism correlated to colon cancer risk in farmers from western region of Inner Mongolia.
Su XL; Yan MR; Yang L;
Chin J Cancer Res; 2012 Dec; 24(4):317-22. PubMed ID: 23358185
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.
Song SY; Jeong SY; Park HJ; Park SI; Kim DK; Kim YH; Shin SS; Lee SW; Ahn SD; Kim JH; Lee JS; Choi EK
Lung Cancer; 2010 May; 68(2):278-82. PubMed ID: 19596483
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.
Siegel D; McGuinness SM; Winski SL; Ross D
Pharmacogenetics; 1999 Feb; 9(1):113-21. PubMed ID: 10208650
[TBL] [Abstract][Full Text] [Related]
11. [The NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and susceptibility to esophageal cancer].
Zhang JH; Li Y; Wang R; Sarbia M; Guo W; Wen DG; Wei LZ; Chen ZF; Kuang G; Zhang LW; He M; Wu ML; Wang SJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Dec; 20(6):544-6. PubMed ID: 14669229
[TBL] [Abstract][Full Text] [Related]
12. Investigation of NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism in prostate cancer.
Ergen HA; Gormus U; Narter F; Zeybek U; Bulgurcuoglu S; Isbir T
Anticancer Res; 2007; 27(6B):4107-10. PubMed ID: 18225579
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
[TBL] [Abstract][Full Text] [Related]
14. [Genetic polymorphisms of NQO1, GSTT1, GSTM1 and susceptibility to chronic benzene poisoning].
Chen Y; Li GL; Ji ZY; Xu JN; Wu CL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2005 Feb; 23(1):1-5. PubMed ID: 15748501
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
[TBL] [Abstract][Full Text] [Related]
16. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
17. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract.
Sarbia M; Bitzer M; Siegel D; Ross D; Schulz WA; Zotz RB; Kiel S; Geddert H; Kandemir Y; Walter A; Willers R; Gabbert HE
Int J Cancer; 2003 Nov; 107(3):381-6. PubMed ID: 14506737
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
[TBL] [Abstract][Full Text] [Related]
19. Review of the management of relapsed small-cell lung cancer with amrubicin hydrochloride.
Kimura T; Kudoh S; Hirata K
Clin Med Insights Oncol; 2011 Mar; 5():23-34. PubMed ID: 21499556
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
